Strong rationale for Vitamin D and ginsenoside metabolites in treating prostate cancer.
Calcitriol and aPPD act synergistically in inhibiting LNCaP and C4-2 cell growth.
Crosstalk between AR and VDR presents a key mechanism for Vitamin D and ginsenosides based therapy.
Combination therapy with aPPD targets distinct molecular pathways and is therefore superior to calcitriol monotherapy.
Synergistic approach could limit calcitriol toxicity by facilitating the use of lower calcitriol doses.